This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Lexaria Bioscience’s 8K filing here.
Lexaria Bioscience Company Profile
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries.
Further Reading
- Five stocks we like better than Lexaria Bioscience
- Breakout Stocks: What They Are and How to Identify Them
- Insiders Are Selling, But These 3 Stocks Are Must-Buys
- Short Selling: How to Short a Stock
- Rivian Defies Doubters: Delivery Triumph Fuels Stock Surge
- What is the Shanghai Stock Exchange Composite Index?
- Hindenburg Short Report Slams Carvana Over Alleged ‘Grift’
